Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein
| Autor: | Simone Jaenisch, Catherine A. Abbott, Roger Yazbeck |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
congenital hereditary and neonatal diseases and abnormalities Dipeptidyl Peptidase 4 Inflammation Plant Science Disease Biology Dipeptidyl peptidase 03 medical and health sciences 0302 clinical medicine Fibroblast activation protein alpha Endopeptidases medicine Humans Dipeptidyl peptidase-4 Autoimmune disease Serine Endopeptidases Cancer Membrane Proteins Cell Biology General Medicine medicine.disease digestive system diseases 030104 developmental biology Gelatinases 030220 oncology & carcinogenesis Immunology Biomarker (medicine) medicine.symptom Biomarkers |
| Zdroj: | Protoplasma. 255(1) |
| ISSN: | 1615-6102 |
| Popis: | The importance of the dipeptidyl peptidase 4 (DPP4) gene family in regulating critical biochemical pathways continues to emerge. The two most well-studied members of the family, DPP4 and fibroblast activation protein (FAP), have been investigated both as therapeutic targets for disease and as diagnostic biomarkers. The interest in DPP4 and FAP as potential disease biomarkers has been driven primarily by observations of altered expression profiles in inflammatory diseases and cancer. Furthermore, the stability and persistence of soluble DPP4 and FAP in the serum make them attractive candidate serology markers. This review summarises investigations into DPP4 and FAP as biomarkers of autoimmune disease, gut inflammation, psychosomatic disorders and malignancy and discusses their potential likelihood as clinically useful tools. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink